Search Results - Mark Konijnenberg

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives by Eline L. Hooijman, Valery Radchenko, Sui Wai Ling, Mark Konijnenberg, Tessa Brabander, Stijn L. W. Koolen, Erik de Blois

    Published in EJNMMI Radiopharmacy and Chemistry (2024-02-01)
    Get full text
    Article


  2. 2

    First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs by Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille

    Published in EJNMMI Radiopharmacy and Chemistry (2023-06-01)
    Get full text
    Article


  3. 3

    Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study by Sui wai Ling, Astrid A. M. van der Veldt, Mark Konijnenberg, Marcel Segbers, Eline Hooijman, Frank Bruchertseifer, Alfred Morgenstern, Erik de Blois, Tessa Brabander

    Published in BMC Cancer (2024-01-01)
    Get full text
    Article


  4. 4

    Effect of epigenetic treatment on SST2 expression in neuroendocrine tumour patients by Julie Refardt, Maria J. Klomp, Peter M. vanKoetsveld, Fadime Dogan, Mark Konijnenberg, Tessa Brabander, Richard A. Feelders, Wouter W. deHerder, Leo J. Hofland, Johannes Hofland

    Published in Clinical and Translational Medicine (2022-07-01)
    Get full text
    Article


  5. 5

    Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals by Carolline M. Ntihabose, Maryana Handula, Amber Piet, Savanne Beekman, Louise van Dalen, Negin Eskandari, Asude Aydogan, Debra Stuurman, Corrina de Ridder, Mark Konijnenberg, Yann Seimbille, Erik de Blois

    Published in EJNMMI Radiopharmacy and Chemistry (2025-10-01)
    Get full text
    Article


Search Tools: